Loading…
Interactions of Cisplatin and Daunorubicin at the Chromatin Level
Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism in vitro . We attempted to interpret these effects in terms of the changes elicited by the drugs in the chromatin, the target held primar...
Saved in:
Published in: | Scientific reports 2020-01, Vol.10 (1), p.1107, Article 1107 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83 |
---|---|
cites | cdi_FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83 |
container_end_page | |
container_issue | 1 |
container_start_page | 1107 |
container_title | Scientific reports |
container_volume | 10 |
creator | Firouzi Niaki, Erfaneh Van Acker, Thibaut Imre, László Nánási, Péter Tarapcsák, Szabolcs Bacsó, Zsolt Vanhaecke, Frank Szabó, Gábor |
description | Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism
in vitro
. We attempted to interpret these effects in terms of the changes elicited by the drugs in the chromatin, the target held primarily responsible for the cytotoxicity of both agents. We measured the effect of Cis-Pt on the levels of Dauno in different cell compartments, the effect of Cis-Pt on Dauno-induced nucleosome eviction, and assessed the influence of Dauno on DNA platination in flow- and laser scanning cytometry as well as in laser ablation-inductively coupled plasma-mass spectrometry assays. We show that the two drugs antagonize each other through a decrease of interstrand crosslinks upon co-treatment with Dauno, and also via the diminished Dauno uptake in the presence of Cis-Pt, and both effects are observed already at low Dauno concentrations. At high Dauno concentrations synergy becomes dominant because histone eviction by Dauno intercalation into the DNA is enhanced in the presence of co-treatment with Cis-Pt. These interactions may have an impact on the efficacy of combination treatment protocols, considering the long retention time of DNA adducts formed by both agents. |
doi_str_mv | 10.1038/s41598-020-57702-7 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6981277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2344544885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EolXpD7BAkVgH_GycDVIVXpUqsYG15dhOmyq1i51U4u9xm1LKBm9szVyfuXMBuEbwDkHC7wNFLOcpxDBlWQZxmp2BIYaUpZhgfH7yHoBxCCsYD8M5RfklGBCUczjJ-RBMZ7Y1Xqq2djYkrkqKOmwa2dY2kVYnj7KzzndlrXaFNmmXJimW3q33irnZmuYKXFSyCWZ8uEfg4_npvXhN528vs2I6TxXNaJtmjNA8q3BuJNOKIYNLLiXhOZooiUsKDSHEaA4JUpiVmk6whtGtxohpIzkZgYeeu-nKtdHK2NbLRmx8vZb-SzhZi78dWy_Fwm1F3BPhLIuA2wPAu8_OhFasXOdt9CwwoZRRyjmLKtyrlHcheFMdJyAodsmLPnkRkxf75MUOfXPq7fjlJ-coIL0gxJZdGP87-x_sN04pjog</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2344544885</pqid></control><display><type>article</type><title>Interactions of Cisplatin and Daunorubicin at the Chromatin Level</title><source>PubMed (Medline)</source><source>Full-Text Journals in Chemistry (Open access)</source><source>Publicly Available Content (ProQuest)</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Firouzi Niaki, Erfaneh ; Van Acker, Thibaut ; Imre, László ; Nánási, Péter ; Tarapcsák, Szabolcs ; Bacsó, Zsolt ; Vanhaecke, Frank ; Szabó, Gábor</creator><creatorcontrib>Firouzi Niaki, Erfaneh ; Van Acker, Thibaut ; Imre, László ; Nánási, Péter ; Tarapcsák, Szabolcs ; Bacsó, Zsolt ; Vanhaecke, Frank ; Szabó, Gábor</creatorcontrib><description>Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism
in vitro
. We attempted to interpret these effects in terms of the changes elicited by the drugs in the chromatin, the target held primarily responsible for the cytotoxicity of both agents. We measured the effect of Cis-Pt on the levels of Dauno in different cell compartments, the effect of Cis-Pt on Dauno-induced nucleosome eviction, and assessed the influence of Dauno on DNA platination in flow- and laser scanning cytometry as well as in laser ablation-inductively coupled plasma-mass spectrometry assays. We show that the two drugs antagonize each other through a decrease of interstrand crosslinks upon co-treatment with Dauno, and also via the diminished Dauno uptake in the presence of Cis-Pt, and both effects are observed already at low Dauno concentrations. At high Dauno concentrations synergy becomes dominant because histone eviction by Dauno intercalation into the DNA is enhanced in the presence of co-treatment with Cis-Pt. These interactions may have an impact on the efficacy of combination treatment protocols, considering the long retention time of DNA adducts formed by both agents.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-57702-7</identifier><identifier>PMID: 31980698</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>101/58 ; 13/1 ; 13/31 ; 14/19 ; 14/34 ; 14/35 ; 14/63 ; 631/337/100/101 ; 631/337/100/1701 ; 631/67/1059/99 ; Antagonism ; Antineoplastic Agents - metabolism ; Antineoplastic Agents - pharmacology ; Antitumor agents ; Cell Line, Tumor ; Chemotherapy ; Chromatin ; Chromatin - drug effects ; Chromatin - genetics ; Cisplatin ; Cisplatin - metabolism ; Cisplatin - pharmacology ; Cytometry ; Cytotoxicity ; Daunorubicin ; Daunorubicin - metabolism ; Daunorubicin - pharmacology ; Deoxyribonucleic acid ; DNA ; DNA adducts ; DNA Adducts - drug effects ; DNA, Neoplasm - metabolism ; Dose-Response Relationship, Drug ; Drug Interactions ; Humanities and Social Sciences ; Humans ; Mass spectrometry ; Mass spectroscopy ; multidisciplinary ; Retention time ; Science ; Science (multidisciplinary)</subject><ispartof>Scientific reports, 2020-01, Vol.10 (1), p.1107, Article 1107</ispartof><rights>The Author(s) 2020</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83</citedby><cites>FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83</cites><orcidid>0000-0002-0649-7228 ; 0000-0002-1884-3853</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2344544885/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2344544885?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31980698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Firouzi Niaki, Erfaneh</creatorcontrib><creatorcontrib>Van Acker, Thibaut</creatorcontrib><creatorcontrib>Imre, László</creatorcontrib><creatorcontrib>Nánási, Péter</creatorcontrib><creatorcontrib>Tarapcsák, Szabolcs</creatorcontrib><creatorcontrib>Bacsó, Zsolt</creatorcontrib><creatorcontrib>Vanhaecke, Frank</creatorcontrib><creatorcontrib>Szabó, Gábor</creatorcontrib><title>Interactions of Cisplatin and Daunorubicin at the Chromatin Level</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism
in vitro
. We attempted to interpret these effects in terms of the changes elicited by the drugs in the chromatin, the target held primarily responsible for the cytotoxicity of both agents. We measured the effect of Cis-Pt on the levels of Dauno in different cell compartments, the effect of Cis-Pt on Dauno-induced nucleosome eviction, and assessed the influence of Dauno on DNA platination in flow- and laser scanning cytometry as well as in laser ablation-inductively coupled plasma-mass spectrometry assays. We show that the two drugs antagonize each other through a decrease of interstrand crosslinks upon co-treatment with Dauno, and also via the diminished Dauno uptake in the presence of Cis-Pt, and both effects are observed already at low Dauno concentrations. At high Dauno concentrations synergy becomes dominant because histone eviction by Dauno intercalation into the DNA is enhanced in the presence of co-treatment with Cis-Pt. These interactions may have an impact on the efficacy of combination treatment protocols, considering the long retention time of DNA adducts formed by both agents.</description><subject>101/58</subject><subject>13/1</subject><subject>13/31</subject><subject>14/19</subject><subject>14/34</subject><subject>14/35</subject><subject>14/63</subject><subject>631/337/100/101</subject><subject>631/337/100/1701</subject><subject>631/67/1059/99</subject><subject>Antagonism</subject><subject>Antineoplastic Agents - metabolism</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antitumor agents</subject><subject>Cell Line, Tumor</subject><subject>Chemotherapy</subject><subject>Chromatin</subject><subject>Chromatin - drug effects</subject><subject>Chromatin - genetics</subject><subject>Cisplatin</subject><subject>Cisplatin - metabolism</subject><subject>Cisplatin - pharmacology</subject><subject>Cytometry</subject><subject>Cytotoxicity</subject><subject>Daunorubicin</subject><subject>Daunorubicin - metabolism</subject><subject>Daunorubicin - pharmacology</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA adducts</subject><subject>DNA Adducts - drug effects</subject><subject>DNA, Neoplasm - metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Interactions</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>multidisciplinary</subject><subject>Retention time</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kMtOwzAQRS0EolXpD7BAkVgH_GycDVIVXpUqsYG15dhOmyq1i51U4u9xm1LKBm9szVyfuXMBuEbwDkHC7wNFLOcpxDBlWQZxmp2BIYaUpZhgfH7yHoBxCCsYD8M5RfklGBCUczjJ-RBMZ7Y1Xqq2djYkrkqKOmwa2dY2kVYnj7KzzndlrXaFNmmXJimW3q33irnZmuYKXFSyCWZ8uEfg4_npvXhN528vs2I6TxXNaJtmjNA8q3BuJNOKIYNLLiXhOZooiUsKDSHEaA4JUpiVmk6whtGtxohpIzkZgYeeu-nKtdHK2NbLRmx8vZb-SzhZi78dWy_Fwm1F3BPhLIuA2wPAu8_OhFasXOdt9CwwoZRRyjmLKtyrlHcheFMdJyAodsmLPnkRkxf75MUOfXPq7fjlJ-coIL0gxJZdGP87-x_sN04pjog</recordid><startdate>20200124</startdate><enddate>20200124</enddate><creator>Firouzi Niaki, Erfaneh</creator><creator>Van Acker, Thibaut</creator><creator>Imre, László</creator><creator>Nánási, Péter</creator><creator>Tarapcsák, Szabolcs</creator><creator>Bacsó, Zsolt</creator><creator>Vanhaecke, Frank</creator><creator>Szabó, Gábor</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0649-7228</orcidid><orcidid>https://orcid.org/0000-0002-1884-3853</orcidid></search><sort><creationdate>20200124</creationdate><title>Interactions of Cisplatin and Daunorubicin at the Chromatin Level</title><author>Firouzi Niaki, Erfaneh ; Van Acker, Thibaut ; Imre, László ; Nánási, Péter ; Tarapcsák, Szabolcs ; Bacsó, Zsolt ; Vanhaecke, Frank ; Szabó, Gábor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>101/58</topic><topic>13/1</topic><topic>13/31</topic><topic>14/19</topic><topic>14/34</topic><topic>14/35</topic><topic>14/63</topic><topic>631/337/100/101</topic><topic>631/337/100/1701</topic><topic>631/67/1059/99</topic><topic>Antagonism</topic><topic>Antineoplastic Agents - metabolism</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antitumor agents</topic><topic>Cell Line, Tumor</topic><topic>Chemotherapy</topic><topic>Chromatin</topic><topic>Chromatin - drug effects</topic><topic>Chromatin - genetics</topic><topic>Cisplatin</topic><topic>Cisplatin - metabolism</topic><topic>Cisplatin - pharmacology</topic><topic>Cytometry</topic><topic>Cytotoxicity</topic><topic>Daunorubicin</topic><topic>Daunorubicin - metabolism</topic><topic>Daunorubicin - pharmacology</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA adducts</topic><topic>DNA Adducts - drug effects</topic><topic>DNA, Neoplasm - metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Interactions</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>multidisciplinary</topic><topic>Retention time</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Firouzi Niaki, Erfaneh</creatorcontrib><creatorcontrib>Van Acker, Thibaut</creatorcontrib><creatorcontrib>Imre, László</creatorcontrib><creatorcontrib>Nánási, Péter</creatorcontrib><creatorcontrib>Tarapcsák, Szabolcs</creatorcontrib><creatorcontrib>Bacsó, Zsolt</creatorcontrib><creatorcontrib>Vanhaecke, Frank</creatorcontrib><creatorcontrib>Szabó, Gábor</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Firouzi Niaki, Erfaneh</au><au>Van Acker, Thibaut</au><au>Imre, László</au><au>Nánási, Péter</au><au>Tarapcsák, Szabolcs</au><au>Bacsó, Zsolt</au><au>Vanhaecke, Frank</au><au>Szabó, Gábor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interactions of Cisplatin and Daunorubicin at the Chromatin Level</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-01-24</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>1107</spage><pages>1107-</pages><artnum>1107</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism
in vitro
. We attempted to interpret these effects in terms of the changes elicited by the drugs in the chromatin, the target held primarily responsible for the cytotoxicity of both agents. We measured the effect of Cis-Pt on the levels of Dauno in different cell compartments, the effect of Cis-Pt on Dauno-induced nucleosome eviction, and assessed the influence of Dauno on DNA platination in flow- and laser scanning cytometry as well as in laser ablation-inductively coupled plasma-mass spectrometry assays. We show that the two drugs antagonize each other through a decrease of interstrand crosslinks upon co-treatment with Dauno, and also via the diminished Dauno uptake in the presence of Cis-Pt, and both effects are observed already at low Dauno concentrations. At high Dauno concentrations synergy becomes dominant because histone eviction by Dauno intercalation into the DNA is enhanced in the presence of co-treatment with Cis-Pt. These interactions may have an impact on the efficacy of combination treatment protocols, considering the long retention time of DNA adducts formed by both agents.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31980698</pmid><doi>10.1038/s41598-020-57702-7</doi><orcidid>https://orcid.org/0000-0002-0649-7228</orcidid><orcidid>https://orcid.org/0000-0002-1884-3853</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2045-2322 |
ispartof | Scientific reports, 2020-01, Vol.10 (1), p.1107, Article 1107 |
issn | 2045-2322 2045-2322 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6981277 |
source | PubMed (Medline); Full-Text Journals in Chemistry (Open access); Publicly Available Content (ProQuest); Springer Nature - nature.com Journals - Fully Open Access |
subjects | 101/58 13/1 13/31 14/19 14/34 14/35 14/63 631/337/100/101 631/337/100/1701 631/67/1059/99 Antagonism Antineoplastic Agents - metabolism Antineoplastic Agents - pharmacology Antitumor agents Cell Line, Tumor Chemotherapy Chromatin Chromatin - drug effects Chromatin - genetics Cisplatin Cisplatin - metabolism Cisplatin - pharmacology Cytometry Cytotoxicity Daunorubicin Daunorubicin - metabolism Daunorubicin - pharmacology Deoxyribonucleic acid DNA DNA adducts DNA Adducts - drug effects DNA, Neoplasm - metabolism Dose-Response Relationship, Drug Drug Interactions Humanities and Social Sciences Humans Mass spectrometry Mass spectroscopy multidisciplinary Retention time Science Science (multidisciplinary) |
title | Interactions of Cisplatin and Daunorubicin at the Chromatin Level |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A45%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interactions%20of%20Cisplatin%20and%20Daunorubicin%20at%20the%20Chromatin%20Level&rft.jtitle=Scientific%20reports&rft.au=Firouzi%20Niaki,%20Erfaneh&rft.date=2020-01-24&rft.volume=10&rft.issue=1&rft.spage=1107&rft.pages=1107-&rft.artnum=1107&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-57702-7&rft_dat=%3Cproquest_pubme%3E2344544885%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2344544885&rft_id=info:pmid/31980698&rfr_iscdi=true |